Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Quarterly profitability accompanied lower spending guidance, while the myelofibrosis development program suffered a trial discontinuation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) reported third-quarter 2026 RYTELO net product revenue of $60.1 million, up from the prior quarter. Revenue increased 5% sequentially, while demand rose 10%. Net income was $1.4 million, versus an $18.4 million loss a year earlier.
Geron reiterated expected 2026 RYTELO revenue at the mid-to-high end of $220 million to $240 million and lowered expected operating expenses to $220 million–$230 million from $230 million–$240 million. Cash, restricted cash and marketable securities totaled approximately $339.4 million at September 30.
A staged European launch began for eligible patients with lower-risk myelodysplastic syndromes, a blood cancer; Geron expects availability in Germany by year-end and France in 2027. The Phase 3 IMpactMF trial was discontinued after its independent monitoring committee recommended stopping because it was unlikely to meet its primary overall-survival endpoint.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointRYTELO Q3 2026 net revenue reached $60.1 million, up 5% sequentially versus $47.2 million a year earlier.
- Moderate pointRYTELO demand increased 10% in Q3 2026 compared with Q2 2026.
- Moderate pointOrdering accounts increased roughly 8% in Q3 2026 to approximately 1,700.
- Moderate pointQ3 2026 net income reached $1.4 million, versus an $18.4 million loss; EPS improved to $0.00 from negative $0.03.
- Moderate pointQ3 operating income reached $5.799 million, versus a $13.887 million operating loss a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Geron lowered expected 2026 operating expenses to $220 million–$230 million from $230 million–$240 million.
- Moderate point. Forward-looking: it has not happened yet and may not happen.European launch began; Geron expects availability in Germany by year-end 2026 and France in 2027.
10 minor points
- Minor pointQ3 research and development expenses fell to $12.709 million from $21.070 million a year earlier.
- Minor pointQ3 selling, general and administrative expenses fell to $35.702 million from $39.001 million a year earlier.
- Minor point. Forward-looking: it has not happened yet and may not happen.Geron reiterated expected 2026 RYTELO revenue at the mid-to-high end of $220 million–$240 million.
- Minor pointCash, restricted cash and marketable securities rose to approximately $339.4 million from $326.9 million at June 30.
- Minor pointNine-month product revenue rose to $169.358 million from $135.610 million in 2025.
- Minor pointNine-month net loss narrowed to $18.972 million from $54.638 million; loss per share improved to $0.03 from $0.08.
- Minor pointQ3 interest expense declined to $7.207 million from $8.644 million a year earlier.
- Minor pointNine-month interest expense declined to $21.500 million from $25.360 million in 2025.
- Minor pointRetrospective real-world imetelstat evidence in lower-risk myelodysplastic syndromes was consistent with IMerge.
- Minor pointPost-hoc pooled IMerge analysis suggests early transient blood-cell reductions may predict better therapeutic response.
Negative
- Major pointPhase 3 IMpactMF was discontinued after monitoring committee advice that the primary overall-survival endpoint was unlikely to be met.
- Minor pointQ3 cost of goods sold rose to $6.051 million from $1.043 million, primarily from non-cash inventory-related expenses.
- Minor pointNine-month cost of goods sold rose to $16.983 million from $3.439 million in 2025.
- Minor pointQ3 interest income declined to $3.025 million from $4.264 million a year earlier.
- Minor pointNine-month interest income declined to $9.417 million from $14.072 million in 2025.
Details
Market move: GERN +3.11% vs previous close. Q3 2026 earnings report
On Nov 4, the day this news came out, the latest delayed price for GERN is 3.11% above the previous close. Argus tracked a peak move of +7.2% during the session. Our momentum scanner has recorded 7 alerts for this stock so far that day. The latest delayed price is $0.96. Relative volume is exceptionally heavy at 38.8x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- RYTELO net product revenue
- $60.1 million
- Q3 2026
- Quarter-over-quarter revenue growth
- 5%
- RYTELO net product revenue, Q3 2026 compared with Q2 2026
- Demand growth
- 10%
- Q3 2026 compared with Q2 2026
- 2026 RYTELO revenue guidance
- $220 million to $240 million
- Reiterated at the mid-to-high end of the range
- 2026 operating expense guidance
- $220 million to $230 million
- Lowered from the prior range of $230 million to $240 million
- Net income
- $1.4 million
- Q3 2026, compared with a net loss of $18.4 million in Q3 2025
Previous Earnings Reports
-
RYTELO revenue reached $57.5 million; 2026 revenue and expense guidance were reiterated.
-
RYTELO revenue was $51.8 million, and the company reported a reduced net loss.
-
RYTELO revenue was $47.2 million, compared with $28.2 million a year earlier.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
primary endpoint medical
post-hoc analysis medical
cytopenias medical
telomerase inhibitor medical
chemistry, manufacturing, and controls technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Achieved
Reiterated 2026 RYTELO net product revenue at the mid-to-high end of the
Initiated gated commercial launch to expand RYTELO access to eligible LR-MDS patients in targeted European markets, with availability expected in Germany by end of year
Ended Q3 2026 with cash, cash equivalents, restricted cash, and marketable securities of
Company to host conference call and webcast today, November 4, 2026, at 8:00 a.m. ET
FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported financial results for the third quarter of 2026 and recent business highlights.
“Another quarter of strong RYTELO demand growth reinforces our confidence in the LR-MDS commercial opportunity and our ability to reach more second-line patients. Increased demand growth is being driven by the community practices which, in our view, indicates the potential for RYTELO to have a long growth runway in the U.S.,” said Harout Semerjian, President and Chief Executive Officer of Geron. “Outside the U.S. there is a clear opportunity for us to serve more patients and create additional value by broadening RYTELO’s access. As such, we have initiated a gated commercial launch to bring RYTELO to targeted EU markets with availability in Germany expected by the end of the year. Expanding access to therapies, along with pursing opportunistic innovation, is a key part of building a leading hematology company.”
Recent Business Highlights
- Reported RYTELO net product revenue of
$60.1 million in the third quarter of 2026.- Grew RYTELO demand by
10% in the third quarter 2026, compared to the second quarter 2026. - Increased ordering accounts by roughly
8% in the third quarter 2026 to approximately 1,700.
- Grew RYTELO demand by
- Initiated a gated commercial launch to bring RYTELO to eligible LR-MDS patients in targeted European markets. RYTELO is expected to be available in Germany later this year and France in 2027.
- Exhibited three posters at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, including real-world evidence of imetelstat for the treatment of LR-MDS that was generally consistent with the Phase 3 IMerge trial and an updated post-hoc analysis of the Phase 2 IMbark study of imetelstat for the treatment of relapsed/refractory myelofibrosis.1-3
- Delivered an oral presentation of retrospective real-world evidence of imetelstat in LR-MDS consistent with the IMerge trial along with a poster featuring a post-hoc study from the IMerge trial at the 88th Annual Meeting of the Japanese Society of Hematology (JSH).4-5
- Provided an oral presentation at the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (DGHO, OeGHO, SGMO, SGH) highlighting post-hoc pooled analysis from the IMerge population that suggests transient cytopenias observed early in treatment may be the result of an on-target effect of imetelstat and may be predictive of a better therapeutic response in LR-MDS patients.6
- Nominated for the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases for RYTELO in LR-MDS, an award recognizing extraordinary scientific achievements in transforming health and improving lives.
- Published two manuscripts in peer-reviewed journals highlighting imetelstat’s role in LR-MDS and other hematological diseases:
- “Overall Survival and Long-Term Outcomes from the Randomized, Double-Blind, Placebo-Controlled, Phase III IMerge Trial of Imetelstat for Lower-Risk Myelodysplastic Syndromes” in Haematologica.7
- “Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models” in the Journal of Clinical Medicine.8
- Announced the discontinuation of the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor R/R myelofibrosis based on a recommendation from the independent Data Monitoring Committee (DMC) that the trial was unlikely to meet the primary endpoint of overall survival. There were no new safety signals observed in the trial that change the known safety profile of imetelstat.
Third Quarter 2026 Financial Results
Cash and Marketable Securities
As of September 30, 2026, Geron had approximately
Net Income (Loss)
For the three months ended September 30, 2026, the Company reported a net income of
Revenues
Total product revenue, net for the three months ended September 30, 2026, was
Costs and Operating Expenses
Total costs and operating expenses for the three months ended September 30, 2026, were
Cost of goods sold was approximately
Research and development expenses for the three months ended September 30, 2026, were
Selling, general and administrative expenses for the three months ended September 30, 2026, were
2026 Financial Guidance
For fiscal year 2026, the Company continues to expect RYTELO net product revenue to be at the mid-to-high end of the
Based on current operating plans and assumptions, the Company believes that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future.
Conference Call
Geron will host a conference call at 8:00 a.m. ET on Wednesday, November 4, 2026, to discuss business updates and third quarter 2026 financial results.
A live webcast of the conference call will be available through the Investors section of the Company’s website at www.geron.com. A replay of the webcast will be archived and available on the Company's website.
1. Data presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting: Thomas J, et al. “Early Real-World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review.” Poster #MDS-775. September 9-12, 2026; Houston, TX, USA & Online
2. Data presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting: Kuykendall AT, et al. “Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis from IMbark Versus Real-World Data, and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow Up.” Poster #MPN-269. September 9-12, 2026; Houston, TX, USA & Online
3. Data presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting: Mascarenhas JO, et al. “Correlation Between IL-8 and TNF-Alpha and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus-Associated Kinase Inhibitor in the IMbark Trial.” Poster #MPN-298. September 9-12, 2026; Houston, TX, USA & Online
4. Data presented at the Annual Meeting of the Japanese Society of Hematology: Eid J, et al. “Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic Syndromes: Insights From United States Claims Data.” Oral Presentation #O1-11C-4. October 9-11, 2026; Kyoto, Japan
5. Data presented at the Annual Meeting of the Japanese Society of Hematology: Eid J, et al. “Durable Clinical Outcomes With Imetelstat in Korean Patients With Lower-Risk-Myelodysplastic Syndromes.” Poster #P3-12-5. October 9-11, 2026; Kyoto, Japan
6. Data presented at the Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology: Brauer D, et al. “Telomerase Inhibition With Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes.” Oral Presentation #V755. October 9-12, 2026; Vienna, Austria
7. Santini V, Komrokji RS, Savona MR, et al. Overall survival and long-term outcomes from the randomized, double-blind, placebo-controlled, phase III IMerge trial of imetelstat for lower-risk myelodysplastic syndromes. Haematologica. 2026 Sep 3. doi: 10.3324/haematol.2026.301456. Epub ahead of print. PMID: 42687814.
8. Huang F, Rusbuldt JJ, Luistro L, Colton H, Eid J. Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models. J Clin Med. 2026 Sep 23;15(19):7399. doi: 10.3390/jcm15197399. PMID: 42881859; PMCID: PMC13665851.
About RYTELO (imetelstat)
RYTELO (imetelstat) is an oligonucleotide telomerase inhibitor approved in the U.S. for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.
In addition, RYTELO is approved in the European Union as a monotherapy for the treatment of adult patients with transfusion-dependent anemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.
RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration and the European Commission.
Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) Geron’s 2026 financial guidance, including its expected full year 2026 RYTELO net product revenue range and total operating expense range; (ii) Geron being positioned to build in the future on RYTELO demand and net revenue growth, including in 2027; (iii) Geron’s European lower-risk MDS commercial strategy for RYTELO, including its gated commercial launch in targeted European markets and the expected timing of commercial availability in such markets; (iv) Geron’s 2026 priorities, including remaining focused on growing RYTELO net revenue in the U.S., pursuing pathways to bring RYTELO to patients outside of the U.S., remaining financially disciplined, and evaluating opportunistic innovation; (v) the expected timing of initial data from investigator-sponsored and real-world evidence trials focusing on RYTELO’s mechanistic studies, combinations and sequencing, earlier-line use and new settings; (vi) the pooled analysis from the IMerge population that suggests treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and transfusion independence in LR-MDS; (vii) Geron’s belief that its existing cash, cash equivalents, restricted cash and marketable securities, together with anticipated net revenues from U.S. sales of RYTELO, will be sufficient to fund projected operating requirements for the foreseeable future; and (viii) and other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO for the treatment of certain patients with lower-risk MDS with transfusion dependent anemia and achieves market acceptance across the breadth of the eligible patient segments in RYTELO’s approved indication; (b) whether the FDA, European Commission and other regulatory authorities will approve imetelstat for other indications with labeling claims that are necessary or desirable for the successful commercialization of RYTELO and without significant labeling restrictions or requirements in an approved label; (c) Geron’s plans to commercialize RYTELO outside of the U.S., including Geron’s lack of experience selling, marketing and commercializing an approved drug outside of the U.S., Geron’s reliance on third parties to execute its gated European commercial launch, and risks related to country-by-country pricing and reimbursement, distribution, supply chain and other operational requirements of operating outside of the U.S.; (d) Geron’s future opportunities and plans, including the uncertainty of future revenues, expenses and other financial performance and results, and the related risk that Geron may be unable to meet its 2026 financial guidance; (e) whether Geron overcomes potential delays and other adverse impacts that may be caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing, supply chain, pricing, coverage and reimbursement, market penetration, regulatory, healthcare or geopolitical challenges in order to obtain and maintain the financial resources for and meet expected timelines and planned milestones; (f) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (g) whether any future safety or efficacy results of RYTELO treatment cause its benefit-risk profile to become unacceptable or negatively impact commercialization, regulatory approvals or clinical development; (h) whether imetelstat actually demonstrates disease-modifying activity in patients, including transfusion independence in LR-MDS, and the ability to target the malignant stem and progenitor cells of the underlying disease; (i) whether Geron meets its post-marketing requirements and commitments for RYTELO; (j) whether there are failures or delays in manufacturing or supplying sufficient quantities of RYTELO (imetelstat) or other clinical trial materials that negatively impact commercialization of RYTELO or the conduct and timing of clinical trials; (k) that the expected timing for initial data from investigator-sponsored and real-world evidence trials may be delayed, perhaps significantly; (l) the discontinuation of the Phase 3 IMpactMF trial, including that Geron does not expect to pursue an approval pathway for imetelstat in relapsed/refractory myelofibrosis, will not recover its investment in the trial, and is increasingly dependent on the success of RYTELO in lower-risk MDS; (m) whether Geron stays in compliance with and satisfies its obligations under its debt and synthetic royalty financing agreements; (n) whether Geron successfully manages the changes in its workforce and realizes expected operating expense savings and business efficiencies resulting from its completed strategic restructuring plan; and (o) as it relates to Geron’s belief as to the sufficiency of its cash resources, if Geron does not generate net revenues from commercial sales of RYTELO at the levels it anticipates, if it experiences unforeseen events or chooses to make other investments in its business, or if its assumptions regarding its projected operating expenses are otherwise incorrect, Geron may require additional funding, which may not be available to Geron on commercially-reasonable terms or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s annual report on Form 10-K for the year ended December 31, 2025, Geron’s quarterly reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, and Geron’s upcoming quarterly report on Form 10-Q for the quarter ended September 30, 2026, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.
| GERON CORPORATION | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| (in thousands, except per share data) | 2026 | 2025 | 2026 | 2025 | |||||||||||
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | ||||||||||||
| Revenues: | |||||||||||||||
| Product revenue, net | $ | 60,114 | $ | 47,167 | $ | 169,358 | $ | 135,610 | |||||||
| Royalties | 76 | 60 | 149 | 256 | |||||||||||
| Total revenues | 60,190 | 47,227 | 169,507 | 135,866 | |||||||||||
| Costs and operating expenses: | |||||||||||||||
| Cost of goods sold | 6,051 | 1,043 | 16,983 | 3,439 | |||||||||||
| Research and development | 12,709 | 21,070 | 49,695 | 57,884 | |||||||||||
| Selling, general and administrative | 35,702 | 39,001 | 109,990 | 117,588 | |||||||||||
| Restructuring charges | (71 | ) | - | (622 | ) | - | |||||||||
| Total costs and operating expenses | 54,391 | 61,114 | 176,046 | 178,911 | |||||||||||
| Income (loss) from operations | 5,799 | (13,887 | ) | (6,539 | ) | (43,045 | ) | ||||||||
| Interest income | 3,025 | 4,264 | 9,417 | 14,072 | |||||||||||
| Interest expense | (7,207 | ) | (8,644 | ) | (21,500 | ) | (25,360 | ) | |||||||
| Other income (expense), net | (267 | ) | (161 | ) | (350 | ) | (305 | ) | |||||||
| Net income (loss) | $ | 1,350 | $ | (18,428 | ) | $ | (18,972 | ) | $ | (54,638 | ) | ||||
| Net income (loss) per share: | |||||||||||||||
| Basic | $ | 0.00 | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.08 | ) | ||||
| Diluted | $ | 0.00 | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.08 | ) | ||||
| Weighted-average common shares: | |||||||||||||||
| Basic | 672,293 | 667,102 | 670,799 | 666,397 | |||||||||||
| Diluted | 674,052 | 667,102 | 670,799 | 666,397 | |||||||||||
| GERON CORPORATION | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| September 30, 2026 | December 31, 2025 | |||||
| (in thousands) | (Unaudited) | (Note 1) | ||||
| Current assets: | ||||||
| Cash, cash equivalents and restricted cash | $ | 71,071 | $ | 79,440 | ||
| Current marketable securities | 217,300 | 280,359 | ||||
| Other current assets | 180,371 | 160,472 | ||||
| Total current assets | 468,742 | 520,271 | ||||
| Noncurrent marketable securities | 50,999 | 41,289 | ||||
| Property and equipment, net | 1,106 | 884 | ||||
| Deposits and other assets | 6,259 | 8,096 | ||||
| Total assets | $ | 527,106 | $ | 570,540 | ||
| Current liabilities | $ | 74,248 | $ | 111,542 | ||
| Noncurrent liabilities | 226,163 | 233,126 | ||||
| Stockholders’ equity | 226,695 | 225,872 | ||||
| Total liabilities and stockholders' equity | $ | 527,106 | $ | 570,540 | ||
| Note 1: Derived from audited financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2025. | ||||||
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Geron's Q3 2026 RYTELO sales and earnings?
Geron reported $60.1 million in RYTELO net product revenue and $1.4 million in net income for Q3 2026. Product revenue was $47.2 million a year earlier, when Geron recorded an $18.4 million net loss. Earnings per share were $0.00, compared with a loss of $0.03.
What is Geron's updated 2026 financial guidance?
Geron expects RYTELO net product revenue at the mid-to-high end of $220 million to $240 million and operating expenses of $220 million to $230 million. The revenue outlook was reiterated, while the expense range was reduced from $230 million to $240 million.
Did Geron's discontinued IMpactMF trial reveal new safety concerns?
The Phase 3 IMpactMF trial showed no new safety signals that change imetelstat's known safety profile. The trial evaluated imetelstat in myelofibrosis that was relapsed or refractory to JAK inhibitors, meaning it had returned or had not responded to those treatments.